Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for two of its products, Brimochol PF and CarbacholPF, which are designed to treat presbyopia.
Brimochol PF and Carbachol PF are once-daily pupil adjustment eye drops without preservatives, aimed at correcting the loss of close range vision associated with presbyopia. Brimochol PF is a fixed dose combination of carbachol, a choline preparation, and bromonidine tartrate, an α Compound formula of a 2-receptor agonist. Carbachol PF is a patented, preservative-free formula for carbachol monotherapy. Both investigational therapies induce pupil constriction, creating a pinhole effect that allows only centrally focused light to enter the eye, enhancing the sharpness and clarity of short to medium distance images for activities such as reading, using smartphones, and browsing computer monitors. In the Phase II VIVID study, both drugs achieved their primary and secondary endpoints and demonstrated a level 3 improvement in close range vision after nine hours without affecting hyperopia vision. They also showed good tolerability profiles with no serious side effects.- Flcube.com
